Hepatitis Virus Vaccines: Present Status

SAUL KRUGMAN, M.D.

Professor of Pediatrics, New York University School of Medicine, New York

Received April 26, 1982

During the past decade there has been extraordinary progress toward the development of vaccines for the prevention of type A and type B hepatitis.

The successful propagation of hepatitis A virus in cell culture in 1979 was followed by the preparation of experimental live attenuated hepatitis A vaccines that have been shown to induce antibody in marmosets and chimpanzees and protect immunized marmosets against challenge with hepatitis A virus. The first human immunization trials will begin in mid-1982.

An inactivated hepatitis B vaccine that was licensed in the United States in November 1981 has been shown to be safe, immunogenic, and effective. When this vaccine becomes available for use in July 1982, it will be recommended for persons who are considered to be at increased risk of contracting hepatitis B infection. Future generations of hepatitis B vaccines may be prepared from hepatitis B surface antigen derived from DNA recombinant technology or by in vitro synthesis of HBs Ag determinants by chemical means.

It was in 1947, 35 years ago, that Dorothy Horstmann and her colleagues described two institutional outbreaks of infectious hepatitis, a disease that was formerly called “acute catarrhal jaundice” [1]. Her study demonstrated that the disease was relatively mild and of short duration in children as compared with adults. During that same year MacCallum of Great Britain proposed that the term “type A hepatitis” be designated for infectious hepatitis and “type B hepatitis” for serum hepatitis.

Studies by various investigators during the 1940s and 1950s provided convincing evidence of the existence of two immunologically distinct agents: hepatitis A virus (HAV) and hepatitis B virus (HBV). However, all efforts to identify these agents or to transmit them to animals were unsuccessful. In addition, attempts to propagate these viruses in cell culture also ended in failure during the 1950s and 1960s. In spite of these obstacles, progress toward the development of hepatitis A and B vaccines is very encouraging. The first human trials with an experimental live attenuated hepatitis A vaccine will begin in 1982. In addition, an inactivated hepatitis B vaccine that was licensed in November 1981 will be available for use by July 1982.

The importance of hepatitis A and B as worldwide problems has been well recognized for many years. These infections are major causes of acute and chronic liver disease in developing and developed countries of the world.

VIRAL HEPATITIS IN DEVELOPING COUNTRIES

In general, type A hepatitis is a relatively benign disease in developing countries; it usually occurs as an inapparent infection or mild illness, predominantly in infants
and children. Complications are rare, recovery is usually complete, and most adults are immune. Consequently, there is no urgent need for a hepatitis A vaccine in these areas.

In contrast, type B hepatitis is a more serious infection in children as well as adults; it may be complicated by a chronic hepatitis B carrier state and by chronic active hepatitis that may progress to cirrhosis and primary hepatocellular carcinoma (PHC). The hepatitis B carrier rate in various Asian and African countries has ranged between 10 percent and 20 percent, an indication of the severity and extent of chronic liver disease in these areas. In these countries PHC is the most common type of cancer, accounting for 20 percent to 40 percent of all malignant tumors. Consequently, under the conditions existing in these countries, there is an urgent need for an effective hepatitis B vaccine.

VIRAL HEPATITIS IN DEVELOPED COUNTRIES

The situation is strikingly different in most developed countries where improvements in sanitation and hygiene have been associated with a declining incidence of hepatitis A infection, especially in children. This phenomenon is responsible for the corresponding increase in susceptibility of the adult population. For example, today more than 60 percent of healthy adults in the United States are susceptible to type A hepatitis. Since type A hepatitis is a moderately severe disease in adults, there may be a need for a hepatitis A vaccine to protect those who travel to highly endemic areas or are exposed to immigrants from endemic areas, especially in schools, hospitals, refugee camps, institutions, and other crowded settings. A safe and effective hepatitis B vaccine is needed for high-risk population groups in developed as well as developing countries of the world. Various high-risk groups for whom the vaccine is recommended will be described later.

HEPATITIS A VACCINE

The sequence of events that led to the development of an experimental live attenuated hepatitis A vaccine began 15 years ago. In 1967 Deinhardt and colleagues [2] reported the successful transmission of human HAV to marmoset monkeys. These observations were subsequently confirmed by Mascoli and colleagues [3] and other investigators. In 1973 Feinstone and colleagues [4] identified 27 nm virus-like particles in stools obtained from patients with acute type A hepatitis. These particles were initially identified by immune electronmicroscopy and later they were characterized as RNA viruses closely related to the enterovirus family of agents [5,6].

The availability of a specific antigen (HA Ag) led to the development of specific tests for the identification of both the virus and its antibody (anti-HAV). These serologic tests enabled investigators to identify susceptible chimpanzees, excellent animals models for hepatitis A vaccine studies.

The crucial contribution that led to the development of a hepatitis A vaccine was the successful propagation of human HAV in cell culture in vivo by Provost and Hilleman in 1979 [7]. This important milestone was achieved 30 years after Enders, Weller, and Robbins first cultivated poliovirus in cell culture [8].

Provost and Hilleman cultivated HAV in primary explant cell cultures of marmoset livers and in normal fetal rhesus kidney cell culture (FR K6). The virus was identified by immunofluorescence, immunofluorescence blockade, serum neutralization, immune adherence, radioimmunossay, immune electronmicros-
copy, and marmoset inoculation tests. No cytopathology was observed. These observations were confirmed and extended by Frösner, Deinhardt, and colleagues [9], and by Purcell and colleagues [10]. The virus has been isolated directly from human feces, and it has been propagated in a human diploid cell line.

During the course of a meeting of the U.S.-Japan hepatitis panel in March 1982, Dr. Maurice Hilleman of Merck Institute for Therapeutic Research stated that “attenuated live virus vaccines have been prepared that induce antibody in marmosets and chimpanzees and protect marmosets against challenge infection.” The initial human immunization trials should begin by mid-1982.

HEPATITIS B VACCINE

The prerequisite for the development of poliovaccine, measles, mumps, rubella, and hepatitis A vaccines was the successful cultivation of these agents in cell culture, thereby providing the huge quantities of antigen required for vaccine production. To date, no one has successfully propagated HBV in cell culture. Nevertheless, it has been possible to develop a safe, immunogenic, and effective inactivated hepatitis B vaccine.

The crucial milestone that led to the development of a hepatitis B vaccine was the discovery of the Australia antigen by Blumberg and colleagues in 1965 [11], and its subsequent association with HBV by Prince in 1968 [12]. In 1970 and 1971 our group reported that heat-inactivated serum containing our MS-2 strain of HBV was immunogenic and partially protective [13]. Vaccine development was accelerated in 1973 when Barker and colleagues [14] successfully transmitted HBV to susceptible chimpanzees. This excellent animal model proved to be valuable for evaluation of safety, immunogenicity, and protective efficacy of the vaccine.

Our initial observation, that it was possible to prepare a crude hepatitis B vaccine by the simple procedure of boiling a 1:10 dilution of MS-2 serum in distilled water, was difficult to explain. Later, it became obvious that this unique, complex virus had a surface component, the hepatitis B surface antigen (HBs Ag) that was immunologically distinct from the DNA containing core component, the hepatitis B core antigen (HBc Ag). During the synthesis of HBV in infected hepatocytes, enormous amounts of excess HBs Ag particles are formed and persist in the blood of persons with chronic hepatitis B infection. The blood of hepatitis B carriers that contains between $10^{10}$ and $10^{13}$ HBs Ag particles per ml has proved to be an excellent source of antigen for vaccine production.

In 1975 Purcell and Gerin [15] and Hilleman and colleagues [16] described their initial studies with an inactivated hepatitis B vaccine prepared from purified preparations of HBs Ag. Since 1975 similar vaccines have been developed in France [17], in Holland [18], in Japan, and in China [19]. The procedures involved in the preparation of these subunit vaccines have been described in several publications [15,16]. In general, the steps involve the collection of large quantities of HBs Ag-positive plasma for purification of the HBs Ag particles by ammonium sulfate concentration, isopyknic banding on sodium bromide, rate zonal separation on a sucrose gradient, and digestion with pepsin. A 1:4000 dilution of formaldehyde solution is added to eliminate any potential residual live virus and the final product is formulated in an alum adjuvant. The current licensed Merck vaccine (HEPTAVAX-B, Merck, Sharp & Dohme) contains 20 μg of HBs Ag protein per ml.

The first human trials with the inactivated vaccine were initiated in 1975 after safety, immunogenicity, and efficacy had been demonstrated in chimpanzees.
Studies by various investigators during the subsequent six years culminated in the licensure of inactivated hepatitis B vaccines in France and in the United States in 1981. The inactivated hepatitis B vaccine (HEPTAVAX-B, Merck, Sharp & Dohme) that was licensed for use in the United States was evaluated for safety, immunogenicity, and efficacy in more than 6000 persons.

SAFETY

Clinical reactions in seronegative recipients of vaccine have been minimal and transient. Mild local soreness at the site of inoculation has been the most common side effect. Systemic reactions have been rare. During the course of placebo-controlled, double-blind, randomized studies the incidence of side effects was essentially the same in vaccine and placebo groups [20]. In general, the vaccine has been extremely well tolerated.

IMMUNOGENICITY

In most studies optimum immunogenicity has been achieved by two inoculations of inactivated hepatitis B vaccine given one month apart and followed by a booster dose six months after the first dose. The anti-HBs response in immunocompetent children and adults has ranged between 30 percent and 50 percent after the first dose, 75 percent to 90 percent after the second dose, and over 95 percent after the booster dose at six months. The vaccine has also proved to be highly immunogenic for newborn infants [21,22]. Barin and colleagues [23] immunized 26 Senegalese infants with three inoculations of vaccine containing 5 μg of HBs Ag per dose. The vaccine, given before the babies were one month old, was well tolerated, and it induced an anti-HBs response in 94.7 percent of infants whose prevaccination serum contained no detectable HBs Ag or anti-HBs.

Vaccine-induced antibody has persisted for the three-year period of observation. If these levels decline in the future, a subsequent booster dose will be required. It is anticipated that vaccine-induced anti-HBs should persist for at least five years in those vaccinees who had a good response.

Unfortunately, immunocompromised dialysis patients have not responded to the vaccine as well as healthy adults. Studies to be published by Szmuness and colleagues have revealed an anti-HBs response of 60 percent to 70 percent after three 40 μg doses of hepatitis B vaccine.

EFFICACY

The efficacy of inactivated hepatitis B vaccine was demonstrated by Szmuness and colleagues [20,24] in a superbly designed and implemented placebo-controlled, randomized clinical trial in a high-risk group of male homosexuals. Of 1083 volunteers, 549 received vaccine and 534 received placebo. The results of the study are summarized in Table 1. As indicated in the report by Szmuness and colleagues [24] “the attack rate of hepatitis B virus infections (excluding conversions of anti-HBc alone) was 3.2% in vaccine recipients compared with 25.6% in placebo recipients (p < 0.0001). In those who received all three doses of 40 μg each, the protective efficacy rate was 100%. The vaccine protected against acute hepatitis B, asymptomatic infection, and chronic antigenemia.” Since 20 μg doses of vaccine have been shown to be as immunogenic as 40 μg doses [25,26], and since the presence of anti-HBs has been shown to be indicative of protection, it is reasonable to conclude that three 20 μg doses of vaccine will be protective.
TABLE 1

Attack Rates for Various Categories of Trial End Points in Placebo and Vaccine Recipients

| End Point                                      | Placebo Group | Vaccine Group | Log-Rank Chi-Square | P Value |
|-----------------------------------------------|---------------|---------------|---------------------|---------|
|                                               | No. | Rate | No. | Rate |                               |         |
| Hepatitis B (ALT* > 90 IU only)               | 45  | 18.1 | 7   | 1.4  | 29.66                         | <0.0001 |
| HBV events with ALT > 45 IU                   | 56  | 21.7 | 13  | 3.4  | 29.56                         | <0.0001 |
| All HBsAg-positive events                     | 70  | 24.4 | 11  | 3.0  | 48.63                         | <0.0001 |
| All HBV events, excluding conversion to anti-HBc alone | 73  | 27.1 | 14  | 3.5  | 44.36                         | <0.0001 |
| All HBV events, including anti-HBc conversions| 93  | 35.0 | 29  | 7.6  | 38.77                         | <0.0001 |

*ALT = alanine aminotransferase (SGPT).

Source: Szmuness W et al.: N Engl J Med 303:833, 1980. Reprinted, by permission of the New England Journal of Medicine.

RECOMMENDATION FOR USE OF HEPATITIS B VACCINE

The vaccine is recommended for the protection of infants, children, and adults who are at a high risk of acquiring type B hepatitis [27]. The incidence of past hepatitis B infection in the high-risk groups listed in Table 2 may range between 20 percent and 90 percent, a rate that is fivefold to 18-fold greater than the incidence in such low-risk persons as healthy blood donors.

The decision to test for susceptibility or immunity before immunization will depend predominantly on cost-benefit factors. It is estimated that three doses of vaccine will cost about 100 dollars. Therefore, it would be important to routinely pretest male homosexuals and residents of institutions where hepatitis B infection is highly endemic. For example, only 30 percent to 40 percent of male homosexuals will be susceptible. Pretesting for past infection will save the substantial cost of immunizing 60 percent to 70 percent of those who are immune. As indicated in Table 2, prevaccination testing is recommended for those groups that are in a very high-risk category; it is optional for those in whom the risk is not as great. It should be noted that studies by Dienstag and colleagues [28] have shown that immunization of HBs Ag-positive carriers or immune persons is not associated with untoward side effects.

PASSIVE-ACTIVE IMMUNIZATION

The use of combined passive immunization with hepatitis B immune globulin (HBIG) and active immunization with inactivated hepatitis B vaccine has been studied by Szmuness and colleagues [29]. They demonstrated that passively acquired anti-HBs did not inhibit an active immune response to the vaccine. Studies currently in progress have been designed to evaluate the efficacy of passive-active immunization for postexposure prophylaxis in infants born of mothers who are infectious HBV carriers.
TABLE 2

Recommendations for Use of Inactivated Hepatitis B Vaccine in High-Risk Groups

| High-Risk Group                                      | Dose of Vaccine,* *µg | Prevaccination Tests† |
|------------------------------------------------------|------------------------|-----------------------|
| Health care personnel                                |                        |                       |
| Physicians and dentists                              | 20                     | Optional              |
| Nurses                                               |                        |                       |
| Paramedical and paradental personnel                 |                        |                       |
| Laboratory technicians                               |                        |                       |
| Selected patients in hemodialysis and                |                        |                       |
| hematology/oncology units                            |                        |                       |
| Children with thalassemia and hemophilia             | 10-20                  | Recommended           |
| Residents (clients) and staff of institutions        |                        |                       |
| for the mentally handicapped and their classroom     |                        |                       |
| contacts                                             | 20                     | Recommended           |
| Household contacts of carriers                       | 20                     | Recommended           |
| Classroom contacts of carriers                       | 20                     | Optional              |
| Homosexually active males                            | 20                     | Recommended           |
| Prostitutes                                          | 20                     | Recommended           |
| Users of illicit drugs                               | 20                     | Recommended           |
| Prisoners                                            | 20                     | Optional              |
| Certain military personnel                           | 20                     | Optional              |
| Infants and young children in high-risk areas        | 10-20                  | Optional              |

*Two doses at a one-month interval and a third (booster) dose as six months.
†BsAg and anti-HBs or anti-HBc tests.

Source: Krugman S: JAMA 247:2012, 1982. Copyright 1982, American Medical Association.

FUTURE HEPATITIS B VACCINES

This first generation hepatitis B vaccine will be more expensive than other viral vaccines because of the complex process involved in the purification of HBs Ag prepared from human plasma that is purchased from chronic carriers. If large quantities of HBs Ag can be derived from recombinant DNA technology or in vitro synthesis of HBs Ag determinants by chemical means, future generations of vaccine may be less costly. This goal and its eventual achievement will be essential in order to meet the urgent needs of the developing nations of the world.

REFERENCES

1. Horstmann DM, Havens WP Jr, Deutsch J: Infectious hepatitis in childhood: A report of two institutional outbreaks and a comparison of the disease in adults and children. J Pediatr 30:381–387, 1947
2. Deinhardt F, Holmes AW, Capps RB, et al: Studies on the transmission of human viral hepatitis to marmoset monkeys. I. Transmission of disease, serial passage and description of liver lesions. J Exp Med 125:673–688, 1967
3. Mascoli CC, Ittensohn VM, Villarejos VM, et al: Recovery of hepatitis agents in the marmoset from human cases occurring in Costa Rica. Proc Soc Exp Biol Med 142:276–282, 1973
4. Feinstone SM, Kapikian AZ, Purcell RH: Hepatitis A: Detection by immune electron microscopy of a virus-like antigen associated with acute illness. Science 182:1026–1028, 1973
5. Provost PJ, Walanski BS, Miller WJ, et al: Physical, chemical and morphologic dimensions of human hepatitis A virus strain CR326. Proc Soc Exp Biol Med 148:532–539, 1975
6. Siegl G, Frosner GG: Characterization and classification of virus particles associated with hepatitis A. I. Size, density, and sedimentation. J Virol 26:48–53, 1978
7. Provost PJ, Hilleman MR: Propagation of human hepatitis A virus in cell culture in vitro. Proc Soc Exp Biol Med 159:201–203, 1978
8. Enders JF, Weller T, Robbins F: Cultivation of the Lansing strain of poliomyelitis virus in cultures of various human embryonic tissues. Science 109:85–87, 1949
9. Frösner GG, Deinhardt F, Scheid R, et al: Propagation of human hepatitis A virus in a hepatoma cell line. Infection 7:303–305, 1979
10. Purcell RH: Viral hepatitis: Some unanswered questions and unfinished business. In Virus and Liver. Edited by L. Bianchi, W Gerok, K Sickinger, GA Stalder. Lancaster, England, MTP Press Ltd, 1980, pp 75–82
11. Blumberg BS, Alter HJ, Visnich S: A “new” antigen in leukemia sera. JAMA 191:541–546, 1965
12. Prince AM: An antigen detected in the blood during the incubation period of serum hepatitis. Proc Natl Acad Sci USA 60:814–821, 1968
13. Krugman S, Giles JP, Hammond J: Viral hepatitis, type B (MS-2 strain): Studies on active immunization. JAMA 217:41–45, 1971
14. Barker LF, Chisari FV, McGrath PP, et al: Transmission of type B viral hepatitis to chimpanzees. J Infect Dis 127:648–662, 1973
15. Purcell RH, Gerin JL: Hepatitis B subunit vaccine: A preliminary report of safety and efficacy tests in chimpanzees. Am J Med Sci 270:395–399, 1975
16. Hilleman MR, Buynak EG, Roehm RR, et al: Purified and inactivated hepatitis B vaccine. Progress report. Am J Med Sci 270:401–404, 1975
17. Maupas P, Goudeau A, Coursaget P, et al: Immunization of hepatitis B in man. Lancet i:1367–1370, 1976
18. Reesink HW, Brummelhuis HGJ, Van Elven EH, et al: The preparation and evaluation of a hepatitis B vaccine in the Netherlands. In Viral Hepatitis. Edited by GN Vyas, SN Cohen, R Schmid. Philadelphia, PA, Franklin Institute Press, 1978, p 714
19. Tao CM, Huang TY, Feng PF, et al: A preliminary study on hepatitis B vaccine. Chin Med J (Engl) 4:101–110, 1978
20. Szmuness W, Stevens CE, Harley EJ, et al: Hepatitis B vaccine: Demonstration of efficacy in a controlled clinical trial in a high risk population in the United States. N Engl J Med 303:833–841, 1980
21. Hilleman MR, Buynak EB, McAleer WJ, et al: Newer developments in human hepatitis vaccines. In Perspectives in Virology XI. Edited by M Pollard. New York, Alan R Liss, 1980, pp 219–247
22. Maupas P, Charon J-P, Barin F, et al: Efficacy of hepatitis B vaccine in prevention of early HBs Ag carrier state in children: Controlled trials in an endemic area (Senegal). Lancet i:289–292, 1981
23. Barin F, Goudeau A, Denis F, et al: Immune response in neonates to hepatitis B vaccine. Lancet i:251–253, 1982
24. Szmuness W, Stevens CE, Zang EA, et al: A controlled clinical trial of the efficacy of the hepatitis B vaccine (Heptavax B): A final report. Hepatology 1:377–385, 1981
25. Krugman S, Holley JP Jr, Davidson M, et al: Immunogenic effect of inactivated hepatitis B vaccine: Comparison of 20 μg and 40 μg doses. J Med Virol 8:119–121, 1981
26. Szmuness W, Stevens CE, Harley EJ, et al: The immune response of healthy adults to a reduced dose of hepatitis B vaccine. J Med Virol 8:123–129, 1981
27. Krugman S: The newly licensed hepatitis B vaccine: Characteristics and indications for use. JAMA 247:2012–2015, 1982
28. Dienstag J, Stevens CE, Szmuness W, et al: Immunization of chronic hepatitis B surface antigen carriers with hepatitis B vaccine. Hepatology 1:506, 1981
29. Szmuness W, Stevens CE, Oleszko WR, et al: Passive-active immunization against hepatitis B: Immunogenicity studies in adult Americans. Lancet i:575–577, 1981